Compass Therapeutics, Inc.

Compass Therapeutics is a clinical-stage biopharmaceutical company that develops proprietary antibody-based therapeutics for treating human diseases, primarily solid tumors and hematologic cancers. The company focuses on the biological relationship between angiogenesis, tumor growth, and the immune system. Its pipeline consists of four clinical-stage candidates: tovecimig, an antibody targeting DLL4 and VEGF-A; CTX-471, an agonist antibody targeting CD137; CTX-8371, an antibody targeting PD-1 and PD-L1; and CTX-10726, targeting PD-1 and VEGF-A. The company aims its therapeutic candidates at patients suffering from diverse malignancies, including biliary tract, colorectal, non-small cell lung, and triple-negative breast cancers.

Clinical development activities take place primarily in the United States and South Korea through trials and institutional collaborations. The company maintains an intellectual property estate of nearly one hundred patents and applications worldwide, including issued patents across the United States, China, Japan, Korea, and several other territories. The provided text does not identify the location of the corporate headquarters.

Summary of the business section of Compass Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 39 employees, 25 of which were primarily engaged in research and development and clinical activities.”